Scholarlink

Objectives <p>The aim of this study was to assess the prevalence of anti-dense fine speckled 70 (anti-DFS70) antibodies in a cohort of patients with undifferentiated connective tissue disease (UCTD) and to evaluate the association between anti-DFS70 positivity and clinical characteristics in a tertiary care center.</p> Methods <p>This medical records review study included patients who met established classification criteria for UCTD. Antinuclear antibody (ANA) testing and the detection of ANA/DFS70 autoantibodies were performed using indirect immunofluorescence assay on HEp-2 cells. Laboratory evaluations included erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, anti-cyclic citrullinated peptides, anti-extractable nuclear antigens, anti-DNA, anti-thyroid peroxidase (anti-TPO), and antiphospholipid antibodies. Patients were categorized into two groups based on anti-DFS70 antibody status.</p> Results <p>Anti-DFS70 antibodies were detected in 68 of 555 patients (12.5%). Anti-DFS70-positive patients were significantly younger than antibody-negative patients [42.9 (± 14.3) vs. 48.0 (± 13.3) years, <i>p</i> = 0.003] and had a younger age at diagnosis [40.3 (± 14.4) vs. 45.2 (± 13.7) years, <i>p</i> = 0.006]. Oral aphthae (<i>p</i> = 0.011) and photosensitivity (<i>p</i> = 0.010) were more frequent in the anti-DFS70-positive group. Significant differences were also observed in laboratory findings: anti-TPO [13.2% vs. 5.5%, <i>p</i> = 0.022], ANA positivity [95.6% vs. 85.4%, <i>p</i> = 0.021], anti-PM/Scl [11.8% vs. 1.8%, <i>p</i> &lt; 0.001], anti-histone [4.4% vs. 0.6%, <i>p</i> = 0.027], and β2-glycoprotein I IgM [11.8% vs. 4.9%, <i>p</i> = 0.031] were all significantly higher among anti-DFS70-positive patients. No significant difference was observed between groups regarding active treatments.</p> Conclusion <p>Our study showed higher prevalence of the anti-DFS70 antibody positivity in the UCTD patient population. The isolated presence of anti-DFS70 antibodies, with or without accompanying non-specific antibodies, may be associated with a milder disease profile and a lower likelihood of progression to a defined CTD; however, longitudinal studies are needed to confirm their potential clinical relevance in patient follow-up.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Frequency and clinical effect of the presence of anti-DFS70 antibodies in a large cohort of patients with undifferentiated connective tissue disease

  • 期刊论文

  • 发表日期：

    2026年4月24日

查看全文
  • Hakan Apaydin,
  • Bünyamin Polat,
  • Pınar Akyüz Dağli,
  • Hatice Ecem Konak,
  • Hakan Babaoğlu,
  • Zilan Bazanci̇r-Apaydin,
  • Esra Kayacan-Erdoğan,
  • Berkan Armağan,
  • Şükran Erten,
  • Serdar Can Güven

摘要

Objectives

The aim of this study was to assess the prevalence of anti-dense fine speckled 70 (anti-DFS70) antibodies in a cohort of patients with undifferentiated connective tissue disease (UCTD) and to evaluate the association between anti-DFS70 positivity and clinical characteristics in a tertiary care center.

Methods

This medical records review study included patients who met established classification criteria for UCTD. Antinuclear antibody (ANA) testing and the detection of ANA/DFS70 autoantibodies were performed using indirect immunofluorescence assay on HEp-2 cells. Laboratory evaluations included erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, anti-cyclic citrullinated peptides, anti-extractable nuclear antigens, anti-DNA, anti-thyroid peroxidase (anti-TPO), and antiphospholipid antibodies. Patients were categorized into two groups based on anti-DFS70 antibody status.

Results

Anti-DFS70 antibodies were detected in 68 of 555 patients (12.5%). Anti-DFS70-positive patients were significantly younger than antibody-negative patients [42.9 (± 14.3) vs. 48.0 (± 13.3) years, p = 0.003] and had a younger age at diagnosis [40.3 (± 14.4) vs. 45.2 (± 13.7) years, p = 0.006]. Oral aphthae (p = 0.011) and photosensitivity (p = 0.010) were more frequent in the anti-DFS70-positive group. Significant differences were also observed in laboratory findings: anti-TPO [13.2% vs. 5.5%, p = 0.022], ANA positivity [95.6% vs. 85.4%, p = 0.021], anti-PM/Scl [11.8% vs. 1.8%, p < 0.001], anti-histone [4.4% vs. 0.6%, p = 0.027], and β2-glycoprotein I IgM [11.8% vs. 4.9%, p = 0.031] were all significantly higher among anti-DFS70-positive patients. No significant difference was observed between groups regarding active treatments.

Conclusion

Our study showed higher prevalence of the anti-DFS70 antibody positivity in the UCTD patient population. The isolated presence of anti-DFS70 antibodies, with or without accompanying non-specific antibodies, may be associated with a milder disease profile and a lower likelihood of progression to a defined CTD; however, longitudinal studies are needed to confirm their potential clinical relevance in patient follow-up.